Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

<div>Unadjusted Kaplan-Meier curves comparing survival of malignant pleural mesothelioma (MPM) patients diagnosed before and after the approval of pemetrexed as well as patients having received platinum-based chemotherapy with pemetrexed versus all other chemotherapeutic regimens.</div>

Lung Cancer International

fig2

Figure 2

Figure 2: Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy 